Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Strategic Combinations: Future of OV therapy with reovirus
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5329)
•••
Comment by Noteableon May 31, 2024 7:58pm
111 Views
Post# 36067161

RE:Strategic Combinations: Future of OV therapy with reovirus

RE:Strategic Combinations: Future of OV therapy with reovirusJust to remind you what I said 2.5 years ago ...

September 29, 2021 -
 
"Reovirus, an orally administered oncolytic virus, also enhanced anti-tumor immunity in several preclinical studies [112,113,114]. In a preclinical study, the oral reovirus RC402 elicited potent and long-lasting anti-tumor immunity in distant tumors by enhancing the infiltration of CD8+ cytotoxic T cells and reducing Tregs. Moreover, RC402 cooperated with PD1 blockade to completely regress colon cancer and prolong the survival of tumor-bearing mice [114]. Parakrama et al. also reported that an intravenous administration of reovirus to patients with mCRC resulted in antigen-presenting cell stimulation and CD8+ T cell activation, which can be used as an immunomodulator [115]."
 
Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer
 
https://www.mdpi.com/2072-6694/13/19/4906/htm
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities